CTMS market to reach just under $1B by 2021, led by CROs

The global clinical trial management system (CTMS) market is set to reach $920 million by the start of the next decade, with this growth boosted by contract research orgs.

This is according to a new report by Markets Report Hub, which found that from this year up to 2021 the CTMS market will grow by 11.5%, with the CRO segment forecast to witness the highest growth rate driven by the rising number of clinical trials.

“The adoption of CTMS software is on the rise across the globe as these solutions significantly increase the efficiency and reduce the cost of conducting clinical trials,” the report’s authors note.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

They say that factors such as growing use of CTMS tech during clinical trials coupled with a growing number of clinical trials and rising R&D expenditure of biopharma companies are driving the use of CTMS.

But the report warns that this market is being constrained by a lack of skilled professionals to operate high-tech CTMS solutions, as well as the smaller budgets of SME biopharma companies and small CROs.

Still, the CRO segment of this market is set to witness the highest growth rate while geographically, North America is expected to command the largest share of the global CTMS market in 2016, followed by Europe.

As of last year, the global CTMS market was dominated by Oracle Corporation, Medidata Solutions and Parexel--which together made up about 60% of the market, the authors found.

“New product launches, partnerships, agreements, and collaborations are the major strategies adopted by market players to strengthen their presence and increase their share in the CTMS market,” the report adds.

- check out the report

Related Article:
Chinese CRO R&G buys into Medidata's trial tech

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

The Mayo Clinic tapped data analytics firm nference to build out an AI-powered engine to collate its years of clinical records and pathology work.

At the annual J.P. Morgan Healthcare Conference, major CRO Charles River Laboratories and Takeda announced a new preclinical tie-up.